Drug Trial Radar · NCT05128487
A Study of NDI 1150-101 in Patients With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
106
Planned (sponsor's estimate)
Start
Nov 5, 2021
Primary completion
Feb 2025
Study completion May 2025
Sponsor
- Lead sponsor
- Nimbus Saturn, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as monotherapy or in combination with pembrolizumab in adult patients with advanced solid tumors.
Conditions
- Solid Tumor
- Renal Cell Carcinoma (Kidney Cancer)
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Non-Small Cell Lung Cancer
Interventions
NDI-101150Drug
NDI-101150 capsules
PembrolizumabDrug
Pembrolizumab IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Frequency of dose-limiting toxicities (DLTs)Time frame: Cycle 1 (28 days)
- Part 2: Objective response rate (ORR)Time frame: Up to approximately 34 months
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Honor Health Research Institute
Scottsdale, Arizona
Yale Cancer Center
New Haven, Connecticut
Georgetown University
Washington D.C., District of Columbia
Ocala Oncology Center
Ocala, Florida
Norton Cancer Institute
Louisville, Kentucky
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Henry Ford Cancer
Detroit, Michigan
HealthPartners Cancer Research Center
Saint Paul, Minnesota
Washington University
St Louis, Missouri
Hackensack University
Hackensack, New Jersey
Columbia University Irving Medical Center
New York, New York
Stephenson Cancer Center
Oklahoma City, Oklahoma
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Center for Oncology and Blood Disorders
Houston, Texas
Oncology Consultants
Houston, Texas
NEXT Oncology
San Antonio, Texas
NEXT Oncology
Fairfax, Virginia
Northwest Medical Specialties
Tacoma, Washington
University of Wisconsin
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.